**3.6 RT-qPCR and Western blot confirmed the effects of ivermectin on the key molecules in energy metabolism pathways at the mRNA and protein levels**

RT-qPCR analysis confirmed the mRNA expression alterations of key molecules in energy metabolism pathways in ovarian cancer cells treated with ivermectin (0 μM, 10 μM, 20 μM, and 30 μM) (**Figure 5**), and further western blot analysis confirmed the protein expression alterations of those corresponding key molecules (**Figure 6**) [21]. These key molecules included PFKP, and PKM in glycolysis pathway, PDHB, CS, IDH2, IDH3A, IDH3B, and OGDHL in Kreb's cycle pathway, ND2, ND5, CYTB, and UQCRH in oxidative phosphorylation pathway, MCT1, and MCT4 in lactate shuttle. These results clearly showed that ivermectin regulated energy metabolism pathways in ovarian cancer cells.

in different concentration of ivermectin groups, with a dose-dependent relationship

*Ivermectin blocked cell cycle progression (A, B, C) and promoted cell apoptosis (D, E) of ovarian cancer cells. Reproduced from Li et al. [21], with copyright permission from nature springer publisher, copyright 2020.*

Wound healing experiment was used to test the effect of ivermectin on cell migration of ovarian cancer cells. The results showed that cell migration was significantly inhibited in cells A2780 and TOV-21G after treatment of 20 μM and

**3.4 Pharmaceutic molecular network predicted the association of ivermectin**

Ingenuity Pathway Analysis (IPA) was used for pharmaceutic molecular network analysis of ivermectin. The results showed that ivermectin was significantly

**3.3 Effect of ivermectin on cell migration in ovarian cancers**

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

(**Figure 2D** and **E**).

**Figure 2.**

**208**

30 μM ivermectin (**Figure 3**) [4].

**with ROS and energy metabolism**

### **Figure 4.**

*Pharmaceutic molecular network predicted the associations of ivermectin with reactive oxygen species (ROS) and energy metabolism pathways (A) Disease and functional analysis of ivermectin based on IPA database (B-G). The association of ivermectin with PKM (B), OGDHL (C), ND2 (D), UQCRH (E), ND5 (F), and CYTB (G). Reproduced from Li et al. [21], with copyright permission from nature springer publisher, copyright 2020.*

### **3.7 Ivermectin regulated lncRNA-EIF4A3-mRNA axis in ovarian cancer cells**

Our quantitative mitochondrial proteomics data identified 1198 differentially mitochondrial proteins (mtDEPs) in human ovarian cancer tissues relative to control ovary tissues [11, 23]. Six RNA-binding proteins among those 1198 mtDEPs were identified, including EIF4A3, SFRS1, IGF2BP2, UPF1, C22ORF28, and EWSR1. Of them, only EIF4A3 was predicted to bind to the mRNA of key molecules in energy metabolism pathways. Further, Starbase predicted 3636 EIF4A3-biding mRNAs in various cancer; and of them, 306 EIF4A3-binding mRNAs was associated

**Pathway**

**211**

Glycolysis pathway

 PFKAP H3BQ34

ODPB

K4EN11

ENOA

F5GXY2

Q5U077

A0A0A0MTS2

Q6IRT1

B3KUV2

H3BRS6

AL1B1

ALDH2

 ALDH2

Aldehyde

dehydrogenase,

mitochondrial

 ALDH1B1

Aldehyde

dehydrogenase

 X,

mitochondrial

0.00E

69821000

 196750000

 0.45

+00

0.00E

812240000

1822600000

 0.44

+00

 ADPGK

 ACSS2

 cDNA FLJ40707 fis, clone

THYMU2026835,

synthetase,

ADP-dependent

 glucokinase

 (Fragment)

 cytoplasmic

 highly similar to

Acetyl-coenzyme

 A

9.53E-03 5.31E-04

11465000

 18413000

 0.69

9455200

 25758000

 0.73

 ADH5

 GPI

Glucose-6-phosphate

S-(hydroxymethyl)glutathione

dehydrogenase

 isomerase (Fragment)

 LDHB

 LDHA

L-lactate

dehydrogenase

L-lactate

dehydrogenase

 A chain (Fragment)

 ENO1

 GAPDH

 PDHB

 Pyruvate

dehydrogenase

 E1 component GAPDH (Fragment)

Alpha-enolase

 subunit beta,

mitochondrial

 0.00E

407280000

1649500000

 0.46

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

+00

0.00E

0

0/

+00

0.00E

54687000000

125660000000

 0.44

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

+00

1.00E

10379000

 29470000

 0.34

+00

0.00E

27852000000

66990000000

 0.42

+00

1.00E

56685000

 138520000

 0.44

+00

0.00E

1308100000

 3513700000

 0.45

+00

 PKM

 PFKP

ATP-dependent

Pyruvate kinase

6-phosphofructokinase,

 platelet type

0.00E

14226000000

25587000000

 0.54

+00

7.46E-03

10727000

 0

+

**Protein ID**

 **Gene**

**Protein name**

**Qvalue**

**Intensity H Intensity L Ratio H/L**

**name**


### *The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.95556*

**3.7 Ivermectin regulated lncRNA-EIF4A3-mRNA axis in ovarian cancer cells**

*Pharmaceutic molecular network predicted the associations of ivermectin with reactive oxygen species (ROS) and energy metabolism pathways (A) Disease and functional analysis of ivermectin based on IPA database (B-G). The association of ivermectin with PKM (B), OGDHL (C), ND2 (D), UQCRH (E), ND5 (F), and CYTB (G). Reproduced from Li et al. [21], with copyright permission from nature springer publisher, copyright 2020.*

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

**Figure 4.**

**210**

Our quantitative mitochondrial proteomics data identified 1198 differentially mitochondrial proteins (mtDEPs) in human ovarian cancer tissues relative to control ovary tissues [11, 23]. Six RNA-binding proteins among those 1198 mtDEPs were identified, including EIF4A3, SFRS1, IGF2BP2, UPF1, C22ORF28, and

EWSR1. Of them, only EIF4A3 was predicted to bind to the mRNA of key molecules in energy metabolism pathways. Further, Starbase predicted 3636 EIF4A3-biding mRNAs in various cancer; and of them, 306 EIF4A3-binding mRNAs was associated


**Pathway**

**213**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue**

**Intensity H Intensity L Ratio H/L**

**name**

A0A024R0Y5

Q6P6D7

A0A3B3ITK7

PGM2

A0A024R5Z9

Kreb's cycle

ODPB

B4DJV2

IDHP

IDH3A

A0A087WZN1

OGDHL

O75944

A0A384MTT2

 PCK2

Epididymis

 secretory sperm binding protein

 ACON

 OGDHL

2-oxoglutarate

Aconitase (Fragment)

dehydrogenase-like,

mitochondrial

 IDH3B

Isocitrate

dehydrogenase

 [NAD] subunit,

mitochondrial

 IDH3A

Isocitrate

dehydrogenase

 [NAD] subunit alpha,

 IDH2

Isocitrate

dehydrogenase

 [NADP],

mitochondrial

mitochondrial

0.00E

268600000

 1119300000

 0.40

+00

0.00E

142630000

 477180000

 0.41

+00

0.00E

17707000

 119970000

 0.56

+00

0.00E

0

 48304000

—

+00

0.00E

403190000

1032500000

 0.56

+00

 CS

 PDHB

 Pyruvate

dehydrogenase

 E1 component Citrate synthase

 subunit beta,

mitochondrial

 0.00E

407280000

1649500000

 0.46

+00

0.00E

2428500000

 5338700000

 0.45

+00

0.00E

1281200000

2994300000

 0.46

+00

 PKM2

 PGM2

 PGM1

 PGAM1

 PFKM

ATP-dependent

Phosphoglycerate

 mutase

Phosphoglucomutase-1

Phosphoglucomutase-2

Pyruvate kinase

6-phosphofructokinase

0.00E

1677600000

3768800000

 0.47

+00

0.00E

11906000000

30409000000

 0.36

+00

0.00E

721450000

1641900000

 0.43

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

+00

0.00E

144180000

 423580000

 0.40

+00

1.00E

35541000

 125430000

 0.54

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

+00


### *The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.95556*

**Pathway**

**212**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue** 0.00E

225000000

 394360000

 0.55

+00

0.00E

529020000

1322400000

 0.48

+00

0.00E

1104800000

2650700000

 0.43

+00

**Intensity H Intensity L Ratio H/L**

**name**

AL3A2

AL9A1

A0A024QZ64

H0YDD4

A0A024R713

Q6FHV6

ENOB

B4DG62

HKDC1

PCKGC

A0A384MTT2

A0A024RBX9

PFKAL

 PFKL

ATP-dependent

6-phosphofructokinase,

 liver type

 PDHA1

Pyruvate

dehydrogenase

 E1 component

 subunit alpha

 PCK2

Epididymis

 secretory sperm binding protein

 PCK1

Phosphoenolpyruvate

carboxykinase,

 cytosolic [GTP]

 HKDC1

Hexokinase

 HKDC1

 HK1

cDNA FLJ56506, highly similar to

Hexokinase-1

 ENO3

 ENO2

 DLD

 DLAT

Acetyltransferase

 component

 of pyruvate

Dihydrolipoyl

ENO2 protein

Beta-enolase

dehydrogenase

dehydrogenase

 complex (Fragment)

 0.00E

530720000

 1251100000

 0.46

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

+00

0.00E

632170000

1843800000

 0.52

+00

0.00E

618190000

 2887100000

 0.26

+00

0.00E

215810000

 482340000

 0.59

+00

0.00E

1617000000

4075800000

 0.53

+00

0.00E

132850000

 568430000

 0.30

+00

0.00E

1267700

 160370000

 0.07

+00

0.00E

403190000

1032500000

 0.56

+00

0.00E

457490000

1353000000

 0.49

+00

0.00E

1242500000

 2567300000

 0.52

+00

 ALDOC

 ALDH9A1

 ALDH3A2

Aldehyde

dehydrogenase

4-trimethylaminobutyraldehyde

Fructose-bisphosphate

 aldolase

dehydrogenase

 family 3 member A2


**Pathway**

**215**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue**

**Intensity H Intensity L Ratio H/L**

**name**

A0A024QZ30

SDHB

D3DVH1

B7ZAF6

Q6IAL5

Oxidative

D2Y6X2

A0A1B0TCA9

Q567R0

C9J8T6

Q6FGA0

U3L4G0

X2C5C9

A0A346M047

 COX2

Cytochrome

 c oxidase subunit II (Fragment)

 COX1

 ATP6

 COX7A2L

 COX17

Cytochrome

 c oxidase copper chaperone

COX7A2L protein

ATP synthase subunit a

Cytochrome

 c oxidase subunit 1

 UQCRH

 CYTB

 ND5

phosphorylation

 SUCLG1

Succinate–CoA

 ligase NADH

dehydrogenase

Cytochrome

 b (Fragment)

UQCRH protein

 subunit 5 (Fragment)

[ADP/GDP-forming]

 subunit alpha,

mitochondrial

 0.00E

261580000

1105700000

 0.34

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

+00

5.33E-04 3.59E-03 0.00E

252050000

 546900000

 0.51

+00

0.00E

7643200

 53020000

 0.36

+00

5.34E-04 0.00E

193600000

 355900000

 0.73

+00

7.89E-04 0.00E

1046600000

2406000000

 0.38

+00

21347000

 57543000

 0.38

22802000

 1280400

 17.81

53396000

 59765000

 0.55

4125200

 24591000

 0.41

 SUCLA2

Succinate–CoA

 ligase

[ADP-forming]

 subunit beta,

mitochondrial

 0.00E

114900000

 726200000

 0.33

+00

 SDHC

 Succinate

dehydrogenase

 complex, subunit C, integral membrane protein,

15 kDa, isoform CRAa

 SDHB

 Succinate

dehydrogenase

[ubiquinone]

 iron–sulfur

 subunit,

mitochondrial

 0.00E

143030000

 516360000

 0.37

+00

0.00E

68060000

 130150000

 0.46

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

+00

 SDHA

 Succinate

dehydrogenase

[ubiquinone]

 flavoprotein

 subunit,

mitochondrial

 0.00E

1096500000

2950800000

 0.44

+00


### *The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.95556*

**Pathway**

**214**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue** 0.00E

5856200000

14406000000

 0.42

+00

**Intensity H Intensity L Ratio H/L**

**name**

Q0QF37

A0A024R325

Q71UF1

A0A024R1Y2

H0YDD4

A0A024R713

Q6IBS5

A0A0S2Z4C3

IDH3G

ODO1

A0A494C101

PCKGC

A0A024RBX9

 PDHA1

Pyruvate

dehydrogenase

 E1 component

 subunit alpha

 PCK1

Phosphoenolpyruvate

carboxykinase,

 cytosolic [GTP]

 PC

Pyruvate carboxylase,

mitochondrial

 (Fragment)

 OGDH

2-oxoglutarate

dehydrogenase,

mitochondrial

 IDH3G

Isocitrate

dehydrogenase

 [NAD] subunit gamma,

mitochondrial

 0.00E

55446000

 230380000

 0.54

+00

0.00E

325090000

 949610000

 0.43

+00

7.83E-04 0.00E

1267700

 160370000

 0.07

+00

0.00E

457490000

1353000000

 0.49

+00

3454600

 19685000

 0.28

 FH

Epididymis

 secretory sperm binding protein (Fragment)

 DLST

 DLD

 DLAT

Acetyltransferase

 component

 of pyruvate

Dihydrolipoyl

DLST protein

dehydrogenase

dehydrogenase

 complex (Fragment)

 0.00E

530720000

 1251100000

 0.46

+00

0.00E

632170000

1843800000

 0.52

+00

0.00E

601540000

 1338700000

 0.53

+00

0.00E

1498700000

3849500000

 0.43

+00

 ACLY

 ACO2

 SUCLG2

Succinate–CoA

 ligase Aconitate hydratase,

ATP-citrate

 synthase

mitochondrial

[GDP-forming]

 subunit beta,

mitochondrial

 0.00E

232210000

 779800000

 0.41

+00

1.00E

0

 12950000

—

+00

0.00E

2033900000

4490700000

 0.46

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

+00

 MDH2

Malate

dehydrogenase

 (Fragment)


**Pathway**

**217**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue** 0.00E

98038000

 557300000

 0.35

+00

0.00E

258530000

 806720000

 0.31

+00

0.00E

1191800000

3218800000

 0.37

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

+00

0.00E

583390000

2310600000

 0.35

+00

0.00E

105790000

 524300000

 0.36

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

+00

 0.00E

226190000

 457540000

 0.46

+00

0.00E

72747000

 287010000

 0.62

+00

0.00E

121660000

 150890000

 0.58

+00

0.00E

33783000

 166330000

 0.37

+00

0.00E

52507000

 160350000

 0.47

+00

0.00E

251800000

 620670000

 0.40

+00

0.00E

489640000

 1451700000

 0.67

+00

0.00E

237370000

 754990000

 0.33

+00

**Intensity H Intensity L Ratio H/L**

**name**

VPP1

R4GN72

VATA

VATB2

A0A024R9I0

Q53Y06

A4D1K0

A0A024R883

A0A024R7X3

COX15

A0A343FH12

H3BNX8

COX5B

 COX5B

Cytochrome

 c oxidase subunit 5B,

mitochondrial

 COX5A

Cytochrome

 c oxidase subunit 5A,

mitochondrial

 COX3

 COX15

Cytochrome

 c oxidase assembly protein COX15 homolog

Cytochrome

 c oxidase subunit 3

 ATP6V1H

 ATP6V1G1

 ATP6V1F

 ATP6V1E1

 ATPase, H+

transporting,

V-type proton ATPase subunit F

V-type proton ATPase subunit G

V-type proton ATPase subunit H

 lysosomal 31 kDa, V1 subunit E isoform 1

 ATP6V1C1

V-type proton ATPase subunit C

 ATP6V1B2

V-type proton ATPase subunit B, brain isoform

 ATP6V1A

V-type proton ATPase catalytic subunit A

 ATP6V0D1

V-type proton ATPase subunit d 1

 ATP6V0A1

V-type proton ATPase 116 kDa subunit a isoform 1

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*


### *The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.95556*

**Pathway**

**216**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue**

**Intensity H Intensity L Ratio H/L**

**name**

H3BNI4

Q496I0

COX6C

COX41

AT12A

ATPG

ATPD

ATP5I

ATPK

E9PN17

Q5QNZ2

ATP5H

ATPO

 ATP5PO

 ATP5PD

ATP synthase subunit d,

ATP synthase subunit O,

mitochondrial

mitochondrial

 ATP5PB

ATP synthase F(0) complex subunit B1,

 ATP5MG

 ATP5MF

 ATP5ME

ATP synthase subunit e,

ATP synthase subunit f,

ATP synthase subunit g,

mitochondrial

mitochondrial

mitochondrial

mitochondrial

 ATP5F1D

ATP synthase subunit delta,

mitochondrial

 ATP5F1C

ATP synthase subunit gamma,

mitochondrial

 ATP12A

 COX4I1

Cytochrome

 c oxidase subunit 4 isoform 1,

Potassium-transporting

 ATPase alpha chain 2

mitochondrial

0.00E

1057000000

2524600000

 0.40

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

+00

1.00E

25608000

 48153000

 0.50

+00

0.00E

610730000

 1752800000

 0.61

+00

0.00E

173290000

 378660000

 0.59

+00

0.00E

139860000

 416580000

 0.28

+00

0.00E

146600000

 369660000

 0.57

+00

0.00E

501810000

1039800000

 0.45

+00

0.00E

1074900000

2486300000

 0.46

+00

0.00E

525070000

 965510000

 0.39

+00

0.00E

1495600000

3024300000

 0.56

+00

 COX6C

Cytochrome

 c oxidase subunit 6C

 COX7A2

 ATP6V0C

V-type proton ATPase proteolipid

COX7A2 protein

 subunit

1.00E

11819000

 33788000

 0.47

+00

0.00E

223550000

 687660000

 0.32

+00

0.00E

24314000

 57899000

 0.34

+00


**Pathway**

**219**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue**

**Intensity H Intensity L Ratio H/L**

**name**

H3BPJ9

NDUBB

C9JKQ2

NDUB4

NDUB8

A0A3B3IT57

E5KRK5

NDUS2

NDUS3

H0Y9M8

Q6IBA0

B7Z4P1

E9PKH6

 NDUFS8

 NADH

dehydrogenase

[ubiquinone]

 iron–sulfur

(Fragment)

 protein 8,

mitochondrial

0.00E

25384000

 70988000

 0.38

+00

 NDUFS7

 cDNA FLJ58024, highly similar to

 NDUFS5

 NADH

dehydrogenase

(Ubiquinone)

 Fe-S protein 5, 15 kDa

reductase)

NADH–ubiquinone

subunit,

mitochondrial

oxidoreductase

 20 kDa

3.38E-03

89666000

 146530000

 1.06

(NADH-coenzyme

 Q

0.00E

13539000

 83631000

 0.36

+00

 NDUFS4

 NADH

dehydrogenase

[ubiquinone]

 iron–sulfur

(Fragment)

 protein 4,

mitochondrial

0.00E

22776000

 124620000

 0.20

+00

 NDUFS3

 NADH

dehydrogenase

[ubiquinone]

 iron–sulfur

 protein 3,

mitochondrial

 0.00E

303550000

1007100000

 0.38

+00

 NDUFS2

 NADH

dehydrogenase

[ubiquinone]

 iron–sulfur

 protein 2,

mitochondrial

 0.00E

255210000

 555800000

 0.40

+00

 NDUFS1

Mitochondrial

NADH–ubiquinone

oxidoreductase

 75 kDa subunit

 0.00E

87635000

1424000000

 0.27

+00

 NDUFB9

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

 subunit 9

 0.00E

47909000

 178250000

 0.26

+00

 NDUFB8

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

 subunit 8,

mitochondrial

 0.00E

38897000

 134110000

 0.34

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

+00

 NDUFB4

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

 subunit 4

 0.00E

15764000

 129660000

 0.40

+00

 NDUFB3

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

 subunit 3 (Fragment)

 7.84E-04

19660000

 91217000

 0.33

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

 NDUFB11

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

mitochondrial

 subunit 11,

 NDUFB10

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

 subunit 10

 0.00E

68400000

 353550000

 0.41

+00

0.00E

40408000

 192110000

 0.31

+00


### *The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.95556*

**Pathway**

**Pathway**

**218**

**Protein ID**

 **Gene**

**Protein name**

**Qvalue** 0.00E

278190000

1028600000

 0.28

+00

0.00E

426190000

 876770000

 0.51

+00

**Intensity H Intensity L Ratio H/L**

**name**

CX6B1

CY1

Q5T1Z0

D8VCQ0

Q7Z518

NDUAD

NDUA2

NDUA4

NDUA5

NDUA8

NDUA9

H3BNK3

NDUB1

 NDUFB1

 NADH

dehydrogenase

[ubiquinone]

 1 beta subcomplex

 subunit 1

 0.00E

52572000

 104780000

 0.46

+00

 NDUFAB1

 NDUFA9

 NADH

dehydrogenase

[ubiquinone]

 1 alpha subcomplex

mitochondrial

Acyl carrier protein (Fragment)

 subunit 9,

 NDUFA8

 NADH

dehydrogenase

[ubiquinone]

 1 alpha subcomplex

 subunit 8

 0.00E

75771000

 226560000

 0.33

+00

0.00E

38134000

 212250000

 0.38

+00

0.00E

91383000

 220140000

 0.41

+00

 NDUFA5

 NADH

dehydrogenase

[ubiquinone]

 1 alpha subcomplex

 subunit 5

 0.00E

126370000

 440540000

 0.46

+00

 NDUFA4

 NDUFA2

 NADH

dehydrogenase

Cytochrome

 c oxidase subunit NDUFA4

[ubiquinone]

 1 alpha subcomplex

 subunit 2

 0.00E

35677000

 165030000

 0.24

+00

0.00E

99542000

1041400000

 0.28

+00

 NDUFA13

 NADH

dehydrogenase

[ubiquinone]

 1 alpha subcomplex

 subunit 13

 0.00E

43461000

 261780000

 0.34

+00

 NDUFA10

 NADH

dehydrogenase

[ubiquinone]

 1 alpha subcomplex

mitochondrial

 subunit 10,

0.00E

46879000

 194320000

 0.31

+00

 ND4

NADH–ubiquinone

oxidoreductase

 chain 4 (Fragment)

 LHPP

Phospholysine

phosphohistidine

 inorganic

pyrophosphate

 phosphatase

 9.74E-03 3.36E-03

3604800

 7493900

 0.44

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

0

 20832000

—

 CYC1

Cytochrome

 c1, heme protein,

mitochondrial

 COX6B1

Cytochrome

 c oxidase subunit 6B1


**Pathway**

**221**

Lactate shuttle

 B4E106

MOT4

**Table 1.** *SILAC quantitative* *(SILAC: L) 20 μM ivermectin*

*expressed value 0 in both H and L groups. Ratio H/L means the ratio of the* 

*with copyright permission*

 *from nature springer publisher,*

 *copyright 2020.*

 *proteomics*

 *revealed the protein expression changes of key molecules in energy metabolic pathways in ovarian cancer cells TOV-21G*

 *for 24 h. - means the protein expressed in L group but not in H group. + means the protein expressed in H group but not in L group. /means the protein with*

*ivermectin-treated*

 *group (SILAC: H) to the no* 

*ivermectin-treated*

 *group (SILAC: L). Reproduced*

 *from Li et al. [21],*

*The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer*

 MCT4

Monocarboxylate

 transporter

 4

 MCT1

cDNA FLJ53399, highly similar to

Monocarboxylate

 transporter

 1

 0.00E

23799000

 115420000

 0.53

+00

0.00E

818320000

2103700000

 0.38

*DOI: http://dx.doi.org/10.5772/intechopen.95556*

+00

 *treated with (SILAC: H) and without*

**Protein ID**

 **Gene**

**Protein name**

**Qvalue**

**Intensity H Intensity L Ratio H/L**

**name**


*SILAC quantitative proteomics revealed the protein expression changes of key molecules in energy metabolic pathways in ovarian cancer cells TOV-21G treated with (SILAC: H) and without (SILAC: L) 20 μM ivermectin for 24 h. - means the protein expressed in L group but not in H group. + means the protein expressed in H group but not in L group. /means the protein with expressed value 0 in both H and L groups. Ratio H/L means the ratio of the ivermectin-treated group (SILAC: H) to the no ivermectin-treated group (SILAC: L). Reproduced from Li et al. [21], with copyright permission from nature springer publisher, copyright 2020.*
